Evaluation of the Risk of Infection During Fever in Labor
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jul 18, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the risk of infection in pregnant women who experience fever during labor. Fever can happen to more than 8% of women in labor and can be caused by different factors, including infections, medication side effects, or just the body’s natural response to labor. The researchers want to gather more information about how often infections occur in these cases and what might predict them. They aim to study this from various medical perspectives, including obstetrics, infectious diseases, and microbiology, to get a clearer picture.
To participate in this study, women must be at least 37 weeks pregnant and have a fever during labor, which is defined as a temperature above 38°C (100.4°F) measured at least twice in a short period. They should be giving birth at one of the participating hospitals between July 1, 2023, and June 1, 2024, and must agree to allow their health data to be collected for research purposes. Women who are less than 37 weeks pregnant, minors, or those who oppose the collection of their data will not be eligible. Participants can expect to be part of a comprehensive study that may help improve understanding and treatment of fever during labor in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women at least more than 37 weeks
- • Who have not opposed the collection of their health data for the purposes of studies and analyzes
- • In work between 07/01/2023 and 06/01/2024
- • Admitted to the work room at Port Royal, Necker Sick Children or Trousseau
- • With fever defined as a tympanic temperature \> 38°C at least 2 times at 10 min intervals during labor.
- Exclusion Criteria:
- * Pregnant women :
- • \< 37NT
- • express their opposition to the collection of their data for research purposes
- • minors or under legal protection
- • context of medical termination of pregnancy or fetal death
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, Idf, France
Paris, Idf, France
Paris, Idf, France
Patients applied
Trial Officials
Caroline CHARLIER, MD, PhD
Principal Investigator
Infectious diseases department of Cochin hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported